JonesResearch analyst Catherine Novack adjusted the firm’s price target on Dare Bioscience to $13 from $5 and keeps a Buy rating on the shares following completion of a 2:1 reverse stock split. The firm also modified its Ovaprene market model based on a longer expected study duration and delayed commercial launch. It expects FDA feedback on the Phase 3 trial design for Sildenafil cream by the end of 2024, with possible pivotal initiation in 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DARE:
- Dare Bioscience downgraded to Hold from Buy at Maxim
- Dare Bioscience announces additional data for Phase 2b RESPOND study
- Dare Bioscience target adjusted to $12 from $6 at H.C. Wainwright
- Daré Bioscience Announces Publication in The Journal of Sexual Medicine of Positive Findings from the Phase 2b RESPOND Clinical Study of Sildenafil Cream, 3.6%
- Closing Bell Movers: Rumble jumps 8% on earnings